TLRY — Tilray Brands, Inc.

Is TLRY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Strong Oversold As of November 17, 2026

Tilray Brands, Inc. (TLRY) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $2.34. The rating moved from Overbought to Strong Oversold on November 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Tilray Brands, Inc. (TLRY) shows a mixed fundamental profile: diversified revenue streams and recent cost and margin improvements provide stabilization, while ongoing debt and historical dilution remain meaningful constraints. Growth catalysts include international expansion and any favorable U.S. policy developments, but earnings and price performance will remain volatile and closely tied to sector sentiment. Short-term upside is possible if execution on margins and distribution continues, yet regulatory and financing risks could sharply impact the equity.

Key factors

  • Market position in cannabis (adult-use and medical) with international exposure across Canada, Europe and select U.S. state markets
  • Revenue diversification from U.S. craft cannabis, Canadian packaged goods, and ancillary products (beverages, hemp/CBD), supporting top-line resilience
  • Ongoing cost-cutting and margin-improvement initiatives that have reduced cash burn and improved near-term operating leverage
  • Historical balance-sheet improvement versus peak leverage, but still meaningful debt and past convertible securities that can dilute equity
  • Macro and sentiment sensitivity — cannabis equities often move with risk-on flows and earnings momentum rather than macro shocks
  • Potential upside from incremental U.S. legislative progress or expanded medical adoption in international markets

Risks

  • Federal illegality in the U.S. and uncertain regulatory/legal framework that could restrict market access or banking/operational capabilities
  • Dilution risk from convertible debt, equity raises or financing activity which has historically pressured share price
  • Commodity and pricing pressure in cannabis products leading to margin compression as competition intensifies and supply normalizes
  • Execution risk in integrating international businesses, launching new product lines, and achieving consistent retail distribution gains
  • High volatility and sensitivity to market sentiment, earnings beats/misses and sector-specific headlines
  • Macroeconomic slowdown or tighter discretionary spending that reduces demand for adult-use cannabis products

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TLRY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.